Table 2.

Characteristics of the studies included in the meta-analysis.

Overall population
Study	Age (years)	Duration (weeks)	Drugs	Dosage (mg)	Placebo number of pts	PDE5 number of pts
McVary et al., 2007 [113]	60	12	Sildenafil	50 (2 weeks); 100	155	168
McVary et al., 2007 [114]*	61.5	12	Tadalafil	5 (6 weeks); 20	126	125
Stief et al., 2008 [115]	55.9	8	Vardenafil	10	110	105
Roehrborn et al, 2008 [116]*	62.0	12	Tadalafil	2.5; 5; 10; 20	185	701
Porst et al., 2009 [117]*	61.9	12	Tadalafil	2.5; 5; 10; 20	105	386
Tamimi et al., 2010 [118]*	60.9	12	UK-369003	10; 25; 50, 100	37	246
Porst et al., 2011 [119]	64.8	12	Tadalafil	5	152	148
Egerdie et al., 2012 [120]*	62.5	12	Tadalafil	2.5; 5	200	406
Oelke et al., 2012 [121]	63.6	12	Tadalafil	5	172	171
Brock et al., 2013 [122]	63.3	12	Tadalafil	5	545	544
Dmochwski et al., 2013 [123]	58.6	12	Tadalafil	20	101	99
Yokoyama et al., 2013 [124]*	63.2	12	Tadalafil	2.5; 5	154	306

*The effect derived from a ponderated mean at end point on International Prostate Symptom Score and maximum urinary flow rate were analyzed.